
Validea's latest report indicates Pfizer (PFE), a large-cap biotechnology firm, scored 70% using the Meb Faber Shareholder Yield Investor model, marking its highest rating among 22 guru strategies tracked. While this model prioritizes cash returns to shareholders via dividends, buybacks, and debt paydown, PFE's 70% score falls below the 80% threshold for 'some interest.' The assessment reveals a mixed fundamental picture, with passes in Net Payout Yield, Valuation, and Relative Strength, but failures in key criteria such as Quality and Debt, and the specific Shareholder Yield metric itself.
Pfizer Inc. (PFE) presents a conflicting fundamental profile according to Validea's quantitative analysis using the Meb Faber Shareholder Yield model. The company achieved a score of 70%, its highest among 22 guru strategies tracked, but this figure falls below the 80% threshold that typically indicates model interest. The assessment reveals specific strengths, with PFE passing criteria related to Net Payout Yield, Valuation, and Relative Strength, suggesting favorable characteristics in terms of cash payouts, current market price, and recent stock performance. However, these are offset by significant weaknesses, most notably a failure on the "Quality and Debt" metric, which raises concerns about the firm's balance sheet health. Critically, despite the model's focus on shareholder returns, PFE also failed the headline "Shareholder Yield" criterion itself, indicating that the composite measure of dividends, buybacks, and debt reduction does not meet the strategy's specific requirements, even while the standalone Net Payout Yield passes.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mixed
Sentiment Score
0.00
Ticker Sentiment